Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 25 | 2023 | 112 | 6.040 |
Why?
|
| Prostate | 13 | 2022 | 34 | 3.400 |
Why?
|
| Kidney Neoplasms | 13 | 2023 | 78 | 2.750 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2023 | 46 | 1.940 |
Why?
|
| Image-Guided Biopsy | 11 | 2022 | 37 | 1.660 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 1112 | 1.400 |
Why?
|
| Robotic Surgical Procedures | 4 | 2023 | 33 | 1.140 |
Why?
|
| Robotics | 3 | 2023 | 25 | 1.050 |
Why?
|
| Nephrectomy | 8 | 2017 | 39 | 0.900 |
Why?
|
| Nomograms | 1 | 2021 | 6 | 0.750 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 14 | 0.740 |
Why?
|
| Male | 43 | 2023 | 14772 | 0.720 |
Why?
|
| Humans | 52 | 2023 | 27072 | 0.640 |
Why?
|
| Waiting Lists | 1 | 2017 | 18 | 0.570 |
Why?
|
| Kidney Transplantation | 3 | 2017 | 119 | 0.560 |
Why?
|
| Renal Dialysis | 1 | 2017 | 84 | 0.540 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 4 | 0.520 |
Why?
|
| Retrospective Studies | 13 | 2023 | 3538 | 0.510 |
Why?
|
| Ultrasonography, Interventional | 6 | 2020 | 69 | 0.500 |
Why?
|
| Heterozygote | 1 | 2016 | 100 | 0.500 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 15 | 0.490 |
Why?
|
| Ultrasonography | 6 | 2019 | 227 | 0.460 |
Why?
|
| Biopsy | 6 | 2022 | 201 | 0.450 |
Why?
|
| Laparoscopy | 4 | 2023 | 185 | 0.450 |
Why?
|
| Middle Aged | 28 | 2022 | 8923 | 0.440 |
Why?
|
| Aged | 21 | 2022 | 8997 | 0.430 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 8 | 0.390 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2017 | 33 | 0.380 |
Why?
|
| Perineum | 2 | 2021 | 8 | 0.380 |
Why?
|
| Kidney Diseases | 2 | 2012 | 72 | 0.350 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2021 | 8 | 0.330 |
Why?
|
| Prostatic Hyperplasia | 3 | 2013 | 9 | 0.320 |
Why?
|
| Ureter | 2 | 2023 | 29 | 0.290 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 27 | 0.270 |
Why?
|
| Kidney | 3 | 2023 | 153 | 0.270 |
Why?
|
| Prospective Studies | 6 | 2023 | 1778 | 0.260 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 31 | 0.260 |
Why?
|
| Adult | 14 | 2017 | 7831 | 0.230 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4777 | 0.220 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 18 | 0.210 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 300 | 0.210 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2022 | 2 | 0.200 |
Why?
|
| Cystectomy | 2 | 2019 | 8 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 30 | 0.190 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 5 | 0.180 |
Why?
|
| Prostatectomy | 2 | 2023 | 23 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2004 | 11 | 0.170 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 474 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2019 | 18 | 0.160 |
Why?
|
| Urology | 1 | 2019 | 17 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 44 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 370 | 0.150 |
Why?
|
| Survival Rate | 2 | 2017 | 342 | 0.150 |
Why?
|
| United States | 4 | 2017 | 2035 | 0.150 |
Why?
|
| Female | 14 | 2017 | 15212 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2017 | 2 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2017 | 22 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 56 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 34 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 3 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2017 | 54 | 0.140 |
Why?
|
| Phototherapy | 1 | 2017 | 30 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 21 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2017 | 58 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 38 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 6 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 189 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 3 | 2004 | 7 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 124 | 0.120 |
Why?
|
| Disease Management | 2 | 2016 | 102 | 0.120 |
Why?
|
| Succinate Dehydrogenase | 1 | 2015 | 2 | 0.120 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2015 | 2 | 0.120 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 7 | 0.120 |
Why?
|
| Animals | 5 | 2017 | 3642 | 0.120 |
Why?
|
| Kallikreins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 51 | 0.120 |
Why?
|
| Prognosis | 5 | 2017 | 785 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2013 | 3 | 0.110 |
Why?
|
| SEER Program | 4 | 2015 | 42 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 57 | 0.110 |
Why?
|
| Time Factors | 1 | 2017 | 1433 | 0.110 |
Why?
|
| Urothelium | 1 | 2013 | 5 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 5 | 0.110 |
Why?
|
| Estrogens | 1 | 2013 | 25 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 15 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 75 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 329 | 0.090 |
Why?
|
| Fungal Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Threonine | 1 | 2011 | 9 | 0.090 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 13 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1792 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3485 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2016 | 257 | 0.080 |
Why?
|
| Watchful Waiting | 2 | 2022 | 12 | 0.080 |
Why?
|
| Nitriles | 2 | 2022 | 14 | 0.080 |
Why?
|
| Young Adult | 4 | 2015 | 1994 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 256 | 0.070 |
Why?
|
| Adolescent | 4 | 2015 | 2172 | 0.070 |
Why?
|
| Malacoplakia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pyelonephritis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Tuberculosis, Renal | 1 | 2006 | 1 | 0.070 |
Why?
|
| Emphysema | 1 | 2006 | 4 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 2302 | 0.070 |
Why?
|
| Abscess | 1 | 2006 | 28 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 348 | 0.060 |
Why?
|
| Child | 3 | 2015 | 1295 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 7 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 9 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 13 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 114 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 1 | 2023 | 11 | 0.050 |
Why?
|
| Kidney Pelvis | 1 | 2023 | 16 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2014 | 1890 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 10 | 0.050 |
Why?
|
| Organ Size | 2 | 2013 | 95 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 759 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2017 | 624 | 0.050 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 2 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 198 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 47 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 86 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 105 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 24 | 0.050 |
Why?
|
| Patient Selection | 2 | 2013 | 194 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 22 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 19 | 0.050 |
Why?
|
| HIV Infections | 1 | 2006 | 466 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 3 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 8 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 111 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 7 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 1395 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 363 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 482 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 676 | 0.040 |
Why?
|
| Education | 1 | 2019 | 40 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 39 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2017 | 1 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 3 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 7 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 177 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2002 | 916 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2015 | 2 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 24 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 85 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 78 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 2 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 295 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2014 | 48 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 66 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 7 | 0.030 |
Why?
|
| Dutasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Azasteroids | 1 | 2013 | 2 | 0.030 |
Why?
|
| Finasteride | 1 | 2013 | 3 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 65 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 347 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 41 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 26 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 94 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 30 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 2 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 14 | 0.030 |
Why?
|
| Propionates | 1 | 2013 | 11 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 20 | 0.030 |
Why?
|
| Michigan | 1 | 2013 | 18 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 38 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 18 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 195 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2013 | 30 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 64 | 0.030 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 93 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 174 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 312 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 175 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 27 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 102 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 673 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 381 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 206 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 292 | 0.020 |
Why?
|
| Solvents | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 94 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 481 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 44 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 90 | 0.020 |
Why?
|
| Chaperonins | 1 | 2011 | 1 | 0.020 |
Why?
|
| Casein Kinase II | 1 | 2011 | 2 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 19 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 14 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 17 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 23 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 60 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 149 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 443 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 599 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 766 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 321 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 949 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 891 | 0.020 |
Why?
|
| Thymidine | 1 | 2004 | 6 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 5 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 3 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 21 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 86 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 107 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 46 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 113 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 213 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 13 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2003 | 8 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 50 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 170 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 310 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 4 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 42 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 32 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 37 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 40 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 278 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 664 | 0.010 |
Why?
|